{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:07:46Z","timestamp":1790726866208,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Radiumhemmet"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.canlet.2015.07.017","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T20:10:12Z","timestamp":1437509412000},"page":"76-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells"],"prefix":"10.1016","volume":"367","author":[{"given":"Govindasamy-Muralidharan","family":"Karthik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"L\u00f6vrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorand Levente","family":"Kis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Lindh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Blomquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.07.017_bib0010","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/JCO.2009.27.4290","article-title":"Influence of sex hormones on cancer progression","volume":"28","author":"Folkerd","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","article-title":"Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers","volume":"123","author":"Nadji","year":"2005","journal-title":"Am. J. Clin. Pathol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2015.07.017_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J. Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2015.07.017_bib0030","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0035","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/83.18.1299","article-title":"Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy","volume":"83","author":"Rutqvist","year":"1991","journal-title":"J. Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2015.07.017_bib0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J. Clin. Oncol"},{"issue":"4","key":"10.1016\/j.canlet.2015.07.017_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003370.pub3","article-title":"Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women","author":"Gibson","year":"2009","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.canlet.2015.07.017_bib0050","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.1996.14.9.2584","article-title":"Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy","volume":"14","author":"Kuukasjarvi","year":"1996","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0055","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"Lindstrom","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0060","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.canlet.2015.07.017_bib0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med"},{"key":"10.1016\/j.canlet.2015.07.017_bib0070","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/bjc.2014.398","article-title":"Oestrogen receptors beta1 and betacx have divergent roles in breast cancer survival and lymph node metastasis","volume":"111","author":"Rosin","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2015.07.017_bib0075","doi-asserted-by":"crossref","first-page":"331S","DOI":"10.1158\/1078-0432.CCR-031212","article-title":"Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0080","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2015.07.017_bib0085","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-06-1537","article-title":"Cancer stem cells and metastasis: lethal seeds","volume":"12","author":"Wicha","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cr.7310118","article-title":"Beyond tumorigenesis: cancer stem cells in metastasis","volume":"17","author":"Li","year":"2007","journal-title":"Cell Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0095","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1158\/1078-0432.CCR-09-2933","article-title":"The difficulty of targeting cancer stem cell niches","volume":"16","author":"LaBarge","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.drup.2010.08.001","article-title":"The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches","volume":"13","author":"Lacerda","year":"2010","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.canlet.2015.07.017_bib0105","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/bcr3687","article-title":"Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo","volume":"16","author":"Klevebring","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0110","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/bcr3396","article-title":"Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling","volume":"15","author":"Harrison","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0115","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/labinvest.2014.65","article-title":"Superficial scrapings from breast tumors is a source for biobanking and research purposes","volume":"94","author":"Ma","year":"2014","journal-title":"Lab. Invest"},{"key":"10.1016\/j.canlet.2015.07.017_bib0120","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0955-0674(97)80078-6","article-title":"TOR signalling and control of cell growth","volume":"9","author":"Thomas","year":"1997","journal-title":"Curr. Opin. Cell Biol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.07.017_bib0130","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1073\/pnas.89.19.9267","article-title":"AKT2, a putative oncogene encoding a member of a subfamily of protein-serine\/threonine kinases, is amplified in human ovarian carcinomas","volume":"89","author":"Cheng","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.07.017_bib0135","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ijc.2910640412","article-title":"Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas","volume":"64","author":"Bellacosa","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2015.07.017_bib0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.277.5322.99","article-title":"Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin","volume":"277","author":"Brunn","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.07.017_bib0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/370071a0","article-title":"PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase","volume":"370","author":"Chung","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.07.017_bib0150","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.07.017_bib0155","doi-asserted-by":"crossref","first-page":"21176","DOI":"10.1074\/jbc.270.36.21176","article-title":"Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels","volume":"270","author":"Rosenwald","year":"1995","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.07.017_bib0160","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1073\/pnas.93.3.1065","article-title":"Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E","volume":"93","author":"Rousseau","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.07.017_bib0165","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1093\/emboj\/cdf391","article-title":"Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope","volume":"21","author":"Castedo","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2015.07.017_bib0170","first-page":"62","article-title":"Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents","volume":"57","author":"Decaudin","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0175","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.07.017_bib0180","doi-asserted-by":"crossref","first-page":"e1000121","DOI":"10.1371\/journal.pbio.1000121","article-title":"Regulation of mammary stem\/progenitor cells by PTEN\/Akt\/beta-catenin signaling","volume":"7","author":"Korkaya","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-1-60327-378-7_23","article-title":"Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action","volume":"590","author":"Marsden","year":"2009","journal-title":"Methods Mol. Biol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0190","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","article-title":"A framework for oligonucleotide microarray preprocessing","volume":"26","author":"Carvalho","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2015.07.017_bib0195","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/bioinformatics\/bti270","article-title":"Use of within-array replicate spots for assessing differential expression in microarray experiments","volume":"21","author":"Smyth","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2015.07.017_bib0200","doi-asserted-by":"crossref","first-page":"D354","DOI":"10.1093\/nar\/gkj102","article-title":"From genomics to chemical genomics: new developments in KEGG","volume":"34","author":"Kanehisa","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0205","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0210","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.07.017_bib0215","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1210\/me.2012-1031","article-title":"Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM\/estrogen complexes","volume":"26","author":"Wardell","year":"2012","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0220","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","article-title":"GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor","volume":"23","author":"Davis","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2015.07.017_bib0225","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2407-9-202","article-title":"Breast cancer stem cells: tools and models to rely on","volume":"9","author":"Charafe-Jauffret","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2015.07.017_bib0230","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.4161\/cc.9.14.12371","article-title":"Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs","volume":"9","author":"Cioce","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2015.07.017_bib0235","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.3760\/cma.j.issn.0366-6999.20130227","article-title":"Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties","volume":"126","author":"Liu","year":"2013","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.canlet.2015.07.017_bib0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-013-2760-2","article-title":"Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate","volume":"142","author":"Raffo","year":"2013","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.canlet.2015.07.017_bib0245","doi-asserted-by":"crossref","first-page":"e18810","DOI":"10.1371\/journal.pone.0018810","article-title":"Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments","volume":"6","author":"Ao","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.07.017_bib0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2407-3-13","article-title":"Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications","volume":"3","author":"Nugoli","year":"2003","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2015.07.017_bib0255","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.18632\/oncotarget.3278","article-title":"Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2015.07.017_bib0260","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.4161\/cc.9.17.12731","article-title":"Ketones and lactate \u201cfuel\u201d tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism","volume":"9","author":"Bonuccelli","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2015.07.017_bib0265","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.18632\/oncotarget.2010","article-title":"Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation","volume":"5","author":"Pasto","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2015.07.017_bib0270","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.07.017_bib0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/annonc\/mdu497","article-title":"Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer","volume":"26","author":"Treilleux","year":"2015","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0280","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0285","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-013-2810-9","article-title":"A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure","volume":"143","author":"Massarweh","year":"2014","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.canlet.2015.07.017_bib0290","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.07.017_bib0295","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1073\/pnas.0810956106","article-title":"The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations","volume":"106","author":"Dubrovska","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.07.017_bib0300","doi-asserted-by":"crossref","first-page":"e2220","DOI":"10.1371\/journal.pone.0002220","article-title":"Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer","volume":"3","author":"Yang","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.07.017_bib0305","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity","volume":"10","author":"deGraffenried","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0310","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.017_bib0315","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/bjc.2014.105","article-title":"Lack of correlation of stem cell markers in breast cancer stem cells","volume":"110","author":"Liu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2015.07.017_bib0320","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.physiol.70.113006.100518","article-title":"Estrogen signaling through the transmembrane G protein-coupled receptor GPR30","volume":"70","author":"Prossnitz","year":"2008","journal-title":"Annu. Rev. Physiol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0325","first-page":"504","article-title":"Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K\/AKT signaling in the regulation of endometrial cancer cell proliferation","volume":"27","author":"Wei","year":"2012","journal-title":"Oncol. Rep"},{"key":"10.1016\/j.canlet.2015.07.017_bib0330","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1210\/en.2004-1064","article-title":"Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells","volume":"146","author":"Thomas","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2015.07.017_bib0335","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/mol.106.026344","article-title":"17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30","volume":"70","author":"Vivacqua","year":"2006","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0340","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1210\/me.2005-0280","article-title":"The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells","volume":"20","author":"Vivacqua","year":"2006","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0345","doi-asserted-by":"crossref","first-page":"27008","DOI":"10.1074\/jbc.M403588200","article-title":"The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells","volume":"279","author":"Maggiolini","year":"2004","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.07.017_bib0350","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1210\/mend.14.10.0532","article-title":"Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF","volume":"14","author":"Filardo","year":"2000","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0355","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jsbmb.2014.05.003","article-title":"GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17beta-estradiol in triple-negative breast cancer cells","volume":"143","author":"Yu","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol"},{"key":"10.1016\/j.canlet.2015.07.017_bib0360","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.017","article-title":"Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas","volume":"122","author":"Liu","year":"2009","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.canlet.2015.07.017_bib0365","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2015.07.017_bib0370","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr3598","article-title":"Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment","volume":"16","author":"Beelen","year":"2014","journal-title":"Breast Cancer Res"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515004723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515004723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:34:32Z","timestamp":1717990472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0304383515004723"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.07.017","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}